Longevity & AgingRetro Biosciences Hits $1.8B Valuation Advancing Human Lifespan Extension
Retro Biosciences, a biotech company focused on extending healthy human lifespan, has reached a $1.8 billion valuation after its latest funding round. Backed by OpenAI CEO Sam Altman, the company is now running its first human clinical trial testing an oral drug designed to help the body clear protein aggregates — the toxic clumps linked to Alzheimer's disease progression. Early results show no serious safety concerns so far. The company plans to release initial trial data in August 2026. Beyond Alzheimer's, Retro is developing a broader pipeline that includes gene therapies and cell replacement technologies aimed at reversing biological aging itself, marking a significant shift from lab research into real-world human testing.
